title: [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
abstract: Last years saw the development of anti-angiogenic strategies in the treatment of cancers. Cilengitide (EMD121974; Merck KGaA, Darmstadt, Germany) is a new drug targeting αvβ3 and αvβ5 integrins thanks to a specific peptide called RGD sequence. Cilengitide acts in correlations between endothelial cells, tumor cells and extracellular matrix. The promising results obtained with Cilengitide in vitro, used alone or in combination with cytotoxic chemotherapy or ionizing radiations, could give many hopes especially for the treatment of cerebral tumors. Clinical trials are nowadays ongoing in this indication. The aim of this review is to take stock of the situation on the mechanisms of action of the integrin inhibitor Cilengitide (EMD121974; Merck KGaA, Darmstadt, Germany) with a focus on the first pre-clinical and clinical results.
authors.affiliation: Centre Oscar-Lambret, unité d'oncologie pédiatrique, Lille Cedex, France. p-leblond@o-lambret.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Leblond
authors.forename: Samuel
authors.initials: S
authors.lastname: Meignan
authors.forename: Florence
authors.initials: F
authors.lastname: Le Tinier
authors.forename: Ullrich
authors.initials: U
authors.lastname: Bethe
authors.forename: Amélie
authors.initials: A
authors.lastname: Lansiaux
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004354:Drug Screening Assays, Antitumor; D005109:Extracellular Matrix / Q000502:physiology; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors; D016023:Integrins / Q000037:antagonists & inhibitors* / Q000502:physiology; D058990:Molecular Targeted Therapy; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors; D012910:Snake Venoms / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D039302:Integrin alphaVbeta3; D016023:Integrins; D019030:Receptors, Vitronectin; D012910:Snake Venoms; C064660:integrin alphaVbeta5; C422910:Cilengitide